HMN-214
CAS: 173529-46-9
Ref. 3D-FH170580
1mg | To inquire | |
2mg | To inquire | |
5mg | To inquire | |
10mg | To inquire | |
25mg | To inquire |
Product Information
- (E)-4-[2-[2-[N-Acetyl-N-[(p-methoxyphenyl)sulfonyl]amino]phenyl]ethenyl]pyridine 1-oxide
- Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-
- Acetamide, N-[(4-methoxyphenyl)sulfonyl]-N-[2-[2-(1-oxido-4-pyridinyl)ethenyl]phenyl]-, (E)-
- Hmn-214
- Ivx 214
- N-[(4-Methoxyphenyl)sulfonyl]-N-[2-[(1E)-2-(1-oxido-4-pyridinyl)ethenyl]phenyl]acetamide
HMN-214 is a novel oral prodrug that is being developed as a single agent therapy for the treatment of cancer. HMN-214 is a prodrug of the natural product dihydromyricetin, which inhibits mitochondrial complex I and II. HMN-214 has shown potent antitumor activity in tumor xenografts and demonstrated safety profile in vivo. The drug also induces cancer cell death via a mechanism that involves inhibition of kinase domain phosphorylation, leading to apoptosis induction. HMN-214 has been tested in vitro and in vivo for pharmacokinetics and gene expression profiling with promising results.
Chemical properties
Technical inquiry about: 3D-FH170580 HMN-214
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.